Evidence map›Paper›PMID 41680760›Full record

ReviewJournal of translational medicine2026

Interpreting cancer genetics through a two-step "evolutionary cascade hypothesis": bridging neutral and selective perspectives.

Alessandro Ottaiano, Mariachiara Santorsola, Francesco Sabbatino, Roberto Sirica, Francesco Caraglia, Anna Ceccarelli, Vincenza Granata, Ines Simeone, Silvia Zappavigna, Massimiliano Berretta and 2 more

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alessandro OttaianoIstituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via M. Semmola, 80131, Naples, Italy. a.ottaiano@istitutotumori.na.it.ORCID 0000-0002-2901-3855
Mariachiara SantorsolaIstituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via M. Semmola, 80131, Naples, Italy.
Francesco SabbatinoMedical Oncology, University of Salerno, Via Salvador Allende 43, 84081, Baronissi, Italy.
Roberto SiricaCentro Polidiagnostico Strumentale srl, AMES, Via Padre Carmine Fico 24, 80013, Casalnuovo Di Napoli, Italy.
Francesco CaragliaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Luigi De Crecchio 7, 80138, Naples, Italy.
Anna CeccarelliMedical Oncology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy.
Vincenza GranataIstituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via M. Semmola, 80131, Naples, Italy.
Ines SimeoneUniversity of Naples "Federico II", Via Sergio Pansini 5, 80131, Naples, Italy.
Silvia ZappavignaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Luigi De Crecchio 7, 80138, Naples, Italy.
Massimiliano BerrettaDepartment of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy.
Giovanni SavareseCentro Polidiagnostico Strumentale srl, AMES, Via Padre Carmine Fico 24, 80013, Casalnuovo Di Napoli, Italy.
Michele CaragliaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Via Luigi De Crecchio 7, 80138, Naples, Italy. michele.caraglia@unicampania.it.

Funding

This work was supported by grants from Ministry of Industry and Made in Italy for a project entitled "Targeting epigenetico di precisione dei meccanismi oncogenici in tumori a prognosi sfavorevole - GOAL." NA
6 · The paper itself

Abstract

backgroundDNA mutations are the fundamental engines of cancer, driving its initiation and progression. The forces that fuel malignancy are also the architects of evolution, shaping life through genetic variations. Mutations, in fact, can emerge naturally from endogenous processes, such as oxidative DNA damage or errors in replication, as well as induced by external factors, including cosmic radiation and chemical carcinogens. MAIN BODY: A key question in cancer research is whether tumor evolution is primarily governed by selective bottlenecks, neutral evolution, or dynamic genetic plasticity. In this work, we examine cancer as a disease driven by evolutionary processes rooted in fundamental biological requirements, including sustained proliferation and nutrient utilization. We hypothesize that the accumulation of mutations activates an evolutionary switch, enabling tumor cells to acquire an enhanced capacity for survival, adaptation, and growth at rates far exceeding typical evolutionary timescales. We propose the "evolutionary cascade hypothesis," a unifying framework that integrates these models into a coherent sequence. At its core lies the failure of DNA repair mechanisms, representing a critical transition in cancer progression. This shift marks the transition from an initial non-Darwinian, neutral phase to a Darwinian, more deterministic phase.

conclusionsAs predictive models of tumor evolution advance through genomic big data and artificial intelligence-driven analysis, the future of cancer treatment may extend beyond targeting individual mutations to disrupting the underlying evolutionary mechanisms that sustain malignancy. This paradigm shift could redefine therapeutic strategies and ultimately improve patient outcomes.

Indexed as

Evolution, MolecularModels, GeneticNeoplasmsSelection, GeneticAnimalsBiological EvolutionDNA RepairHumansMutationCancer evolutionCancer geneticsDNA mutationsDNA repairGenomic instability

Identifiers

PMID41680760
PMCPMC13011755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.